Literature DB >> 33923319

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.

Máté A Demény1,2, László Virág1,2.   

Abstract

Poly (ADP-ribose) polymerases (PARPs) modify target proteins with a single ADP-ribose unit or with a poly (ADP-ribose) (PAR) polymer. PARP inhibitors (PARPis) recently became clinically available for the treatment of BRCA1/2 deficient tumors via the synthetic lethality paradigm. This personalized treatment primarily targets DNA damage-responsive PARPs (PARP1-3). However, the biological roles of PARP family member enzymes are broad; therefore, the effects of PARPis should be viewed in a much wider context, which includes complex effects on all known hallmarks of cancer. In the companion paper (part 1) to this review, we presented the fundamental roles of PARPs in intrinsic cancer cell hallmarks, such as uncontrolled proliferation, evasion of growth suppressors, cell death resistance, genome instability, replicative immortality, and reprogrammed metabolism. In the second part of this review, we present evidence linking PARPs to cancer-associated inflammation, anti-cancer immune response, invasion, and metastasis. A comprehensive overview of the roles of PARPs can facilitate the identification of novel cancer treatment opportunities and barriers limiting the efficacy of PARPi compounds.

Entities:  

Keywords:  angiogenesis; anticancer immunity; evasion of immune response; hallmarks of cancer; inflammation; invasion; metastasis; oncogenes; poly (ADP-ribose) polymerase

Year:  2021        PMID: 33923319     DOI: 10.3390/cancers13092057

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  142 in total

1.  Correction for Brady et al., "Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity".

Authors:  Pamlea N Brady; Anupam Goel; Margaret A Johnson
Journal:  Microbiol Mol Biol Rev       Date:  2019-03-13       Impact factor: 11.056

2.  HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition.

Authors:  Xinyan Wu; Hexin Chen; Belinda Parker; Ethel Rubin; Tao Zhu; Ji Shin Lee; Pedram Argani; Saraswati Sukumar
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 3.  Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion.

Authors:  Crescenzo D'Alterio; Stefania Scala; Gabriella Sozzi; Luca Roz; Giulia Bertolini
Journal:  Semin Cancer Biol       Date:  2019-08-24       Impact factor: 15.707

4.  Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase.

Authors:  J G Mabley; P Jagtap; M Perretti; S J Getting; A L Salzman; L Virág; E Szabó; F G Soriano; L Liaudet; G E Abdelkarim; G Haskó; A Marton; G J Southan; C Szabó
Journal:  Inflamm Res       Date:  2001-11       Impact factor: 4.575

Review 5.  Deciphering the insights of poly(ADP-ribosylation) in tumor progression.

Authors:  María Isabel Rodríguez; Jara Majuelos-Melguizo; Juan Manuel Martí Martín-Consuegra; Mariano Ruiz de Almodóvar; Abelardo López-Rivas; Francisco Javier Oliver
Journal:  Med Res Rev       Date:  2015-01-21       Impact factor: 12.944

Review 6.  Cancer as an overhealing wound: an old hypothesis revisited.

Authors:  Matthias Schäfer; Sabine Werner
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07-16       Impact factor: 94.444

7.  Poly(ADP-ribose) polymerase-1 modulates Nrf2-dependent transcription.

Authors:  Tongde Wu; Xiao-Jun Wang; Wang Tian; Melba C Jaramillo; Alexandria Lau; Donna D Zhang
Journal:  Free Radic Biol Med       Date:  2013-10-17       Impact factor: 7.376

8.  Regulation of NF-κB signalling by the mono-ADP-ribosyltransferase ARTD10.

Authors:  Patricia Verheugd; Alexandra H Forst; Larissa Milke; Nicolas Herzog; Karla L H Feijs; Elisabeth Kremmer; Henning Kleine; Bernhard Lüscher
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  PARP-1 and YY1 are important novel regulators of CXCL12 gene transcription in rat pancreatic beta cells.

Authors:  Jelena Marković; Nevena Grdović; Svetlana Dinić; Teodora Karan-Djurašević; Aleksandra Uskoković; Jelena Arambašić; Mirjana Mihailović; Sonja Pavlović; Goran Poznanović; Melita Vidaković
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more
  6 in total

Review 1.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

2.  Tricetin Reduces Inflammation and Acinar Cell Injury in Cerulein-Induced Acute Pancreatitis: The Role of Oxidative Stress-Induced DNA Damage Signaling.

Authors:  Máté Nagy-Pénzes; Zoltán Hajnády; Zsolt Regdon; Máté Á Demény; Katalin Kovács; Tarek El-Hamoly; József Maléth; Péter Hegyi; Csaba Hegedűs; László Virág
Journal:  Biomedicines       Date:  2022-06-10

Review 3.  Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.

Authors:  Stanislas Quesada; Michel Fabbro; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

Review 4.  Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.

Authors:  Stanislas Quesada; Michel Fabbro; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

Review 5.  Functions of ADP-ribose transferases in the maintenance of telomere integrity.

Authors:  Daniela Muoio; Natalie Laspata; Elise Fouquerel
Journal:  Cell Mol Life Sci       Date:  2022-03-29       Impact factor: 9.207

Review 6.  Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Authors:  Tao Xie; Kristie-Ann Dickson; Christine Yee; Yue Ma; Caroline E Ford; Nikola A Bowden; Deborah J Marsh
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.